United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10.

The unituxin market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...

Double-digit growth in key products, including Tyvaso, Remodulin, Orenitram, and Unituxin, contributed to the financial success. United Therapeutics Corporation (NASDAQ:UTHR)’s Tyvaso revenue ...

The company manufactures pharmaceutical drugs such as Adcirca (tadalafil) for PAH, Unituxin (dinutuximab) for high-risk neuroblastoma in pediatric oncology, and prostacyclin analogs (Remodulin ...